Post Reply
1-20 of 40
Looks positive. Now that data/results out and showing Big growth soon. With its products going worldwide, thats the 'catch' imo...
AnthonyWoodPeck ( Date: 13-Feb-2022 09:04) Posted:
This one need to watchlist for the future.
Numbers are showing , company turning around
Last time gap up and kill all. This time round the players maintain the price.
Can tell it is changing its play |
|
This one need to watchlist for the future.
Numbers are showing , company turning around
Last time gap up and kill all. This time round the players maintain the price.
Can tell it is changing its play
💪 ... Loading more when can.... 😄 ...
Joelton ( Date: 12-Feb-2022 11:38) Posted:
iX Biopharma swings into the black in H1 with S$3.7m profit on licensing agreement
CATALIST-LISTED iX Biopharma $ IX Biopharma: 42C +11.98% has swung back into the black with a net profit of S$3.7 million for the first half of its fiscal year ended Dec 31, 2021, compared with a net loss of S$2.8 million the previous year.
The turnaround in profitability was driven by the out-licensing of Wafermine, its lead drug under development, to Seelos Therapeutics in November 2021, iX Biopharma said in a bourse filing on Friday (Feb 11).
This lifted the group' s revenue for H1 2022 to S$13.2 million, up from S$830,000 a year ago. On the back of higher revenue, the group recorded a gross profit of S$12.1 million versus a gross loss of S$160,000 in H1 2021.
Total expenses increased to S$6.9 million in H1 2022, compared with S$5.7 million a year ago. This was mainly due to expenses relating to the group' s out-licensing of Wafermine, which comprised a one-off expense of S$920,000 in legal and advisory fees as well as share-based compensation, and S$940,000 in financial advisor fees and other expenses.
Excluding this one-off expense, the group' s total expenses would have declined by S$690,000 compared with H1 2021.
Earnings per share stood at 0.49 Singapore cents for H1 2021, reversing a loss per share of 0.41 cents in the year before.
No dividend was declared for the half year, unchanged from a year ago, as iX Biopharma said it needs to conserve its cash reserve for the development and commercialisation of products.
In addition to receiving an upfront fee payment of S$1.6 million in January 2022 from its Wafermine licensing agreement, iX Biopharma said the partnership with Seelos Therapeutics could generate additional development and sales " milestone" payments of up to US$239 million and sales royalties for the group, moving forward.
Eddy Lee, chairman and chief executive of iX Biopharma, said the positive set of results marks a " significant inflection point" in the business. The out-licensing of Wafermine is a " validation" of the group' s business model in leveraging its WaferiX technology to repurpose existing approved drugs for new treatments, he added.
" This is really the start of an exciting phase, as we look forward to monetising other drugs in our pipeline in line with our business model."
|
|
iX Biopharma swings into the black in H1 with S$3.7m profit on licensing agreement
CATALIST-LISTED iX Biopharma $ IX Biopharma: 42C +11.98% has swung back into the black with a net profit of S$3.7 million for the first half of its fiscal year ended Dec 31, 2021, compared with a net loss of S$2.8 million the previous year.
The turnaround in profitability was driven by the out-licensing of Wafermine, its lead drug under development, to Seelos Therapeutics in November 2021, iX Biopharma said in a bourse filing on Friday (Feb 11).
This lifted the group' s revenue for H1 2022 to S$13.2 million, up from S$830,000 a year ago. On the back of higher revenue, the group recorded a gross profit of S$12.1 million versus a gross loss of S$160,000 in H1 2021.
Total expenses increased to S$6.9 million in H1 2022, compared with S$5.7 million a year ago. This was mainly due to expenses relating to the group' s out-licensing of Wafermine, which comprised a one-off expense of S$920,000 in legal and advisory fees as well as share-based compensation, and S$940,000 in financial advisor fees and other expenses.
Excluding this one-off expense, the group' s total expenses would have declined by S$690,000 compared with H1 2021.
Earnings per share stood at 0.49 Singapore cents for H1 2021, reversing a loss per share of 0.41 cents in the year before.
No dividend was declared for the half year, unchanged from a year ago, as iX Biopharma said it needs to conserve its cash reserve for the development and commercialisation of products.
In addition to receiving an upfront fee payment of S$1.6 million in January 2022 from its Wafermine licensing agreement, iX Biopharma said the partnership with Seelos Therapeutics could generate additional development and sales " milestone" payments of up to US$239 million and sales royalties for the group, moving forward.
Eddy Lee, chairman and chief executive of iX Biopharma, said the positive set of results marks a " significant inflection point" in the business. The out-licensing of Wafermine is a " validation" of the group' s business model in leveraging its WaferiX technology to repurpose existing approved drugs for new treatments, he added.
" This is really the start of an exciting phase, as we look forward to monetising other drugs in our pipeline in line with our business model."
So far only Phllips securities covering this stock. Need more brokerage house to cover it.
luckyfa ( Date: 12-Feb-2022 10:47) Posted:
Vested some too... As seeing it earning $$ liao and products going world wide... 👍 💪
ahberngh ( Date: 12-Feb-2022 09:16) Posted:
Watch out for IX Biopharma, it could be a " Tiger" stock within 1 or 2 years.
There are too many catalysts for it not to be noticed!
Howver, it is not unusual for biopharma stocks to be " tua ho, tua pai" - literally translated " big good, big bad" , that is to say, one could win big or lose big  .
Let' s hope it is the former (I am vested, so biased  ).
Huat ahhh! |
|
|
|
Vested some too... As seeing it earning $$ liao and products going world wide... 👍 💪
ahberngh ( Date: 12-Feb-2022 09:16) Posted:
Watch out for IX Biopharma, it could be a " Tiger" stock within 1 or 2 years.
There are too many catalysts for it not to be noticed!
Howver, it is not unusual for biopharma stocks to be " tua ho, tua pai" - literally translated " big good, big bad" , that is to say, one could win big or lose big .
Let' s hope it is the former (I am vested, so biased ).
Huat ahhh! |
|
Watch out for IX Biopharma, it could be a " Tiger" stock within 1 or 2 years.
There are too many catalysts for it not to be noticed!
Howver, it is not unusual for biopharma stocks to be " tua ho, tua pai" - literally translated " big good, big bad" , that is to say, one could win big or lose big
.
Let' s hope it is the former (I am vested, so biased
).
Huat ahhh!
Also, hope listing in HK is successful, SGX difficult to increase valuation.
Good news, reporting 1st profit.
Hope more good news coming, FDA approval of Wafermine, .....
ahberngh ( Date: 11-Feb-2022 13:22) Posted:
IX halted, good news coming???
Fingers crossed, Tiger year huat ah! |
|
IX halted, good news coming???
Fingers crossed, Tiger year huat ah!
This licensing agreement are excluded China market and China market still have WAFESIL licensing agreement waiting to approve. Hong KONG listing in progress, so only the time will tell the story.
Already hold for two years, at least now got progress in their business.maybe this year got profit already.Don't need to care for the short term just hold.
safe price to buy is 220/225.. business got development so unlikely to go below 20c.. HUAT!!
This one always like that can not hold for long.
ahberngh ( Date: 24-Nov-2021 10:48) Posted:
SGX for you, ha!ha!.
After good news, drop, nothing more to be said.
|
|
I don't think so. If BB never support, surely this stock got problem. Thought will chiong and I wanted to buy and ride with the dragon. End up it's a worm. Lucky never buy.
piscesmonkey ( Date: 24-Nov-2021 10:41) Posted:
| Shortist attack. Look like shortist dont care about this news |
|
SGX for you, ha!ha!.
After good news, drop, nothing more to be said.
maybe it is a loss-making company and NAV low at 1c.. not for contra..
TheMatrix ( Date: 24-Nov-2021 10:38) Posted:
| Why never chiong? It's a trap maybe... Those buy at 0.260 must be super disappointed 😞 |
|
Shortist attack. Look like shortist dont care about this news
This counter for few rounds always touch 27.5 then back to square one ..thank goodness get out quick ..only if u have patience to wait , see if chng Kay want to push higher or not
Why never chiong? It's a trap maybe... Those buy at 0.260 must be super disappointed 😞
